About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Pennsylvania | 534 Studies

Clinical Trials Ovarian CancerPennsylvania

Ovarian Cancer Clinical Trials in Pennsylvania

Find 534 clinical trials for ovarian cancer near Pennsylvania. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Pennsylvania

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 81-100 of 534 trials

TerminatedA Study Of PF-06263507 In Patients With Advanced Solid TumorsTo assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select…NCT01891669·Boston, Massachusetts and 3 others CompletedA Dose Finding Study of ZW49 in Patients With HER2-Positive CancersThis is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the…NCT03821233·Duarte, California and 15 others TerminatedEvaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsThe objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic…NCT06714617·Denver, Colorado and 8 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedA Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsThe purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and…NCT00841191·Philadelphia, Pennsylvania and 11 others

Active not recruitingStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesThis study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants…NCT04561362·Denver, Colorado and 23 others

CompletedStudy of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant AscitesThe purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.NCT00326885·Tucson, Arizona and 17 others

CompletedA Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerThis is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either…NCT01847274·Phoenix, Arizona and 111 others

CompletedFondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic CancerRATIONALE: Fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer.NCT00381888·Minneapolis, Minnesota and 1 other

RecruitingA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan…NCT06824467·Birmingham, Alabama and 201 others

TerminatedUpifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once…NCT05329545·Phoenix, Arizona and 29 others

CompletedStudy of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced CancersPhase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.NCT02526017·Scottsdale, Arizona and 38 others

RecruitingA Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationPhase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.NCT06778863·Scottsdale, Arizona and 20 others

CompletedBlood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid TumorsThe primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay…NCT03662204·Phoenix, Arizona and 118 others

TerminatedFolate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian CancerThis is a double-blind, randomized, parallel groups Phase II trial.NCT02978222·Birmingham, Alabama and 17 others

RecruitingStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsThis study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated…NCT06128551·Duarte, California and 55 others

TerminatedAtezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerThis randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in…NCT03206047·Tucson, Arizona and 16 others

TerminatedhuCART-meso + VCN-01 in Pancreatic and Ovarian CancerThis is a single-center phase 1 study to evaluate the safety and feasibility of huCART-meso cells given in combination with VCN-01 in patients with unresectable or metastatic…NCT05057715·Philadelphia, Pennsylvania

SuspendedTesting the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsThis phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with…NCT04840589·Bethesda, Maryland and 8 others

CompletedPhase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesThe purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or…NCT03126110·Los Angeles, California and 37 others

Completed3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal CancerDrugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.NCT00081276·Philadelphia, Pennsylvania

PreviousPage 5 of 27Next

Other Conditions in Pennsylvania

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia